Brief: ALX Oncology Q1 Basic EPS USD -0.17
08/05/2026 13:00
May 08 (Reuters) - ALX Oncology Q1 operating expenses USD 18.966 million. Q1 income from operations USD -18.966 million Q1 net income USD -17.927 million Q1 EPS USD -0.17
Recent news on ALX Oncology Holdings
See all newsALX Oncologys' Q1 loss narrows on lower expenses
Brief: ALX Oncology Q1 Basic EPS USD -0.17
Brief: Alx Oncology’S Evorpacept In Combination With Zanidatamab Generates Promising, Durable Response In Patients With Advanced Her2-Positive Breast Cancer And High Cd47 Expression
Brief: Alx Oncology Reports Inducement Grant As Permitted By The Nasdaq Listing Rules
ALX Oncology Q4 loss narrows, names permanent CMO